Curis

Curis Cash Conversion Cycle

The Cash Conversion Cycle (CCC) of Curis (CRIS) as of Nov 20, 2026 is -45,519.56. In the previous year, Cash Conversion Cycle (CCC) was -11,150.79 — a change of 308.22% (lower).

Cash Conversion Cycle

-45,519.56

YoY

308.22%

Last updated:

Cash Conversion Cycle (CCC) of Curis is 2025 -45,519.56 . Cash Conversion Cycle (CCC) of Curis was 2024 -11,150.79 . It decreases by 308.22% lower compared to the previous year.

The Curis Cash Conversion Cycle history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion Cycle
Date
Cash Conversion Cycle
Jan 1, 2018
-2,320.59 USD
Jan 1, 2019
-3,191.47 USD
Jan 1, 2020
-3,019.21 USD
Jan 1, 2021
-6,024.78 USD
Jan 1, 2022
-8,525.84 USD
Jan 1, 2023
-9,554.02 USD
Jan 1, 2024
-11,150.79 USD
Jan 1, 2025
-45,519.56 USD
The Curis Cash Conversion Cycle history
YEARCash Conversion CycleYoY
-45,519.56+308.22%
-11,150.79+16.71%
-9,554.02+12.06%
-8,525.84+41.51%
-6,024.78+99.55%
-3,019.21-5.40%
-3,191.47+37.53%
-2,320.59-40.14%
-3,876.40-39.53%
-6,410.35+34.12%
-4,779.58+60.53%
-2,977.41—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Curis Stock analysis

What does Curis do? Curis Inc generates revenue primarily through the development and potential commercialization of its therapeutic drug candidates in the biotechnology sector. The company focuses on oncology treatments, with its lead candidate Emavusertib targeting IRAK4 kinase inhibition for cancer therapy. Other key products include Erivedge, which inhibits the Hedgehog signaling pathway, and additional candidates like CI-8993, Fimepinostat, CA-170, and CA-327, targeting various cancer-related pathways. The firm conducts R&D internally and via strategic collaborations, aiming to advance these drug candidates toward clinical and commercial stages. Curis Inc's primary buyers are pharmaceutical companies and healthcare institutions seeking innovative cancer treatments. The company's pipeline includes orally available small molecule drugs and monoclonal antibodies designed for targeted cancer therapies. Emavusertib, Erivedge, and CA-170 represent the core product segments, with CA-170 specifically targeting VISTA and PDL1 immune checkpoint proteins. Strategic collaborations support the development of these therapeutics, aligning with the company's focus on oncology drug discovery and development. The company's revenue streams are tied to the progression of its drug candidates through clinical trials and potential partnerships. Emavusertib and Erivedge are in clinical stages, with CA-170 also advancing in development. Curis Inc's business model emphasizes internal R&D alongside strategic alliances to accelerate the development of its pipeline, ensuring that its products reach the market for cancer treatment applications. Curis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Curis stock

Cash Conversion Cycle (CCC) of Curis is -45,519.56 in 2025.

Cash Conversion Cycle (CCC) of Curis changed from -11,150.79 to -45,519.56, representing a 308.22% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Cycle (CCC) Curis since 2006 – with annual values, charts, and detailed analysis.

The Cash Conversion Cycle measures how long it takes to convert inventory investments into cash from sales. A shorter CCC indicates more efficient working capital management.

CCC = DSO + DIO - DPO

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Cycle (CCC)'s Curis with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Cycle (CCC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Cycle (CCC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Curis

All Key Metrics — Curis